PARP inhibitor combination therapy. by Dréan, A et al.
  
 
 
 
 
PARP inhibitor combination therapy 
 
Amy Drean, Christopher J. Lord and Alan Ashworth 
The CRUK Gene Function Laboratory, 
The Breakthrough Breast Cancer Research Centre, 
The Institute of Cancer Research,  
London, SW3 6JB, UK 
Email Chris.Lord@icr.ac.uk  
  
PARPi combination therapy    2 
Abstract 
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) 
polymerase) inhibitor to be approved for the treatment of cancer. When used 
as single agents, PARP inhibitors can selectively target tumour cells with 
BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic 
lethality. However, PARP inhibition shows considerable promise when used 
together with other therapeutic agents. Here, we summarise both the pre-
clinical and clinical evidence for the utility of such combinations and discuss 
the future prospects and challenges for PARP inhibitor combinatorial 
therapies. 
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Introduction 
 
The PARP (Poly(ADP-ribose) polymerase) family of enzymes utilise beta 
nicotinamide adenine dinucleotide (-NAD+) to covalently add Poly(ADP-
ribose) (PAR) chains onto target proteins a process termed PARylation (De 
Vos et al. 2012). This form of post-translational modification has the ability to 
alter the function of target proteins and has been found to be involved in a 
diverse set of cellular processes including chromatin modification, 
transcription regulation, the control of cell division, Wnt signalling and the 
maintenance of telomeres (Gibson and Kraus 2012). The best-studied PARP 
enzyme is PARP1, which has a well-established role in the repair of damaged 
DNA (reviewed in (De Vos et al. 2012)). As part of this role, PARP1 is 
involved in the repair of single stranded DNA breaks (Woodhouse et al. 2008), 
but has also been implicated in the repair of other DNA lesions (Krishnakumar 
and Kraus 2010). PARP1 binds to damaged DNA via a series of Zinc finger 
domains, and then PARylates a series of DNA repair effector proteins as part 
of the repair process, releasing nicotinamide as a by product (Krishnakumar 
and Kraus 2010). Once the role of PARP1 in this repair process is complete, 
PARP1 autoPARylation causes the release of the protein from DNA (De Vos 
et al. 2012).  
 
The role of PARP1 and the related enzyme PARP2, in DNA repair, prompted 
the development of potent small molecule PARP1/2 inhibitors (PARPi) 
(reviewed in (Zaremba and Curtin 2007)). The original proposed use of these 
inhibitors was as chemo- or radiosensitizing agents. Indeed, as early as the 
1980s, a toolbox PARP superfamily inhibitor, 3-aminobenzamide (3AB), was 
shown to enhance the cytotoxic effect of the DNA methylating agent, dimethyl 
sulphate (Purnell and Whish 1980). Classical structure activity relationship-
based drug discovery efforts led to the discovery of the first set of clinical 
PARPi to enter clinical trials; rucaparib (AG014699, PF-01367338/ Pfizer), 
veliparib (ABT-888/Abbott Pharmaceuticals), olaparib (AZD2281, 
KuDOS/AstraZeneca, now marketed as Lynparza), and niraparib (MK-4827, 
Merck/Tesaro) (recently reviewed in (Lord et al. 2015)). In general, these 
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inhibitors tend to have PARP1 IC50 (the drug concentration needed to kill 50% 
of a cell population) values in the nanomolar range, but more recently, a 
second generation of more potent PARPi with picomolar PARP1 IC50 values, 
such as talazoparib (BMN 673, Biomarin/Medivation) have been developed 
(Shen et al. 2013). Each of these small molecule inhibitors impairs the 
catalytic activity of PARP1 by interacting with the -NAD+ binding catalytic 
domain. However, there are distinct differences in other aspects of their 
function. For example, recent work has suggested that the cytotoxicity caused 
by PARPi is in part caused by PARP1 being “trapped” on DNA by PARPi 
(Murai et al. 2012), a likely consequence of impairing PARP1 autoPARylation. 
It seems that whereas drugs such as talazoparib and olaparib are effective 
PARP1 trapping agents, veliparib has considerably less effect in this regard 
(Murai et al. 2012; Murai et al. 2014b).  
 
Although clinical PARPi were developed with a chemo- or radiosensitisation 
role in mind, their utility as single agents has superseded this effort. PARP1/2 
inhibitors can selectively target tumour cells with defects in either the BRCA1 
or BRCA2 tumour suppressor genes that normally maintain the integrity of the 
genome by mediating a DNA repair process, known as homologous 
recombination (HR) (recently reviewed in (Lord et al. 2015)). This “synthetic 
lethal” effect of PARPi is likely caused by PARPi causing a persistent DNA 
lesion that is normally repaired by HR; in the absence of BRCA gene function 
and HR, tumour cells seem unable to effectively repair these DNA lesions and 
die, whilst normal (non-tumour) cells are unaffected (Bryant et al. 2005; 
Farmer et al. 2005). The effectiveness of PARPi in being able to selectively 
target BRCA mutant tumour cells in pre-clinical model systems (tumour cell 
lines and animal models) was reflected in clinical trials where significant and 
sustained anti-tumour responses were observed in heavily pre-treated breast 
or ovarian cancer patients with germ-line BRCA1 or BRCA2 mutations (Lord 
et al. 2015). Additionally, efficacy was observed when olaparib was used in a 
Phase 2 clinical trial as a maintenance therapy in high-grade serous ovarian 
cancer (HGSOC) following carboplatin first-line therapy. For example, when 
compared to patients receiving placebo after carboplatin, HGSOC patients 
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who received olaparib maintenance therapy exhibited a marked improvement 
in progression free survival (PFS) (8.4 months compared to 4.8 months in the 
placebo arm). HGSOC is a disease with a relatively high frequency of BRCA 
mutations and in this same clinical trial, patients harbouring BRCA1 or BRCA2 
gene mutations showed the most profound improvement in PFS (11.2 
months) (Ledermann et al. 2012; Ledermann et al. 2014). On the basis of 
these trial results, olaparib was approved for use by the Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) in 2014, 
specifically as a maintenance monotherapy in patients with deleterious or 
suspected deleterious germline BRCA mutated, advanced ovarian cancer, 
who have been treated with three or more prior lines of chemotherapy (2014; 
Simon 2014).  
 
Although PARPi can elicit profound and sustained anti-tumour responses in 
BRCA-mutant patients, in some cases PARPi resistance emerges (Lord and 
Ashworth 2013). In BRCA mutant patients, clinical PARPi resistance has been 
associated with the presence of additional mutations in the either the BRCA1 
or BRCA2 genes. These “secondary” mutations, which have been observed in 
tumour DNA recovered from patients with profound PARPi resistance (Barber 
et al. 2013), restore the open reading frame (ORF) of either the BRCA1 or 2 
gene and cause the formation of a functional protein product that can restore 
HR and repair the DNA lesion caused by PARPi (Edwards et al. 2008; Sakai 
et al. 2009). Additional mechanisms of acquired resistance to PARPi have 
been proposed and include up-regulation of P-glycoprotein (PGP) pumps 
(which transport small molecules such as PARPi across the plasma 
membrane), additional loss of function in either DNA repair proteins, 53BP1 
and REV7, or stabilization of the BRCT domain of mutant BRCA1 by the heat-
shock protein 90 (HSP90) (Lord and Ashworth 2013). 
 
Further investigation of PARPi utility outwith a BRCA context has also been 
explored. Several sporadic tumours have been shown to exhibit a BRCAness 
phenotype, where they possess molecular and histopathological 
characteristics similar to BRCA-deficient disease (Turner et al. 2004). For 
example, the presence of oncogenic fusions such as EWS-FLI1 (caused by a 
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chromosomal translocation) in Ewing sarcoma (EWS) and subsequently 
derived tumour cell lines and xenografts exhibit sensitivity to PARPi (Brenner 
et al. 2012; Garnett et al. 2012). However, a Phase 2 clinical trial evaluating 
efficacy of a single-agent PARPi therapeutic approach exhibited no partial or 
complete response in 12 Ewing sarcoma patients (NCT01583543) (Choy et 
al. 2014). Defects in the ATM DNA repair tumour suppressor gene have also 
been associated with PARPi sensitivity (McCabe et al. 2006; Williamson et al. 
2010); in contrast to EWS, clinical responses to ATM mutant prostate cancers 
have recently been described (Mateo et al. 2015). 
 
Before we summarize the current understanding of PARPi combinatorial 
effects, it is perhaps useful to consider why combination therapy might be 
useful in contrast to single agent treatment. Combinations of therapeutic 
agents that have fundamentally different mechanisms of action and varying 
normal tissue toxicity have great potential for improving survival outcomes for 
cancer patients. In some instances, some agents fail to have any anti-tumour 
effects when used as single agents, but can elicit effects when combined with 
secondary agents. Although the use of single agent PARPi has received 
considerable attention as of late, a notable amount of data evaluating the 
potential of PARPi in combination has accrued over the last decade. 
Specifically, strategies to optimize the use of PARPi as chemopotentiators, as 
well as to circumvent the development of resistance have been, and remain, 
under investigation.  
 
Combinations of PARPi with Cytotoxic Chemotherapy 
 
Together with radiotherapy and surgery, cytotoxic chemotherapy remains one 
of the core elements of most cancer treatments. However, chemotherapy 
responses are treatments limited by either de novo or acquired resistance and 
therefore combination therapies that improve chemotherapy responses are 
eagerly sought. Many chemotherapies work by causing DNA damage and/or 
exploiting DNA repair defects that exist in tumour cells and therefore 
additional drugs, such as PARP inhibitors, which also impair DNA repair 
processes are often assessed for their ability to enhance chemotherapy 
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responses. As mentioned earlier, the discovery and pre-clinical optimization of 
small molecule PARPi was originally driven by the potential of these agents to 
enhance the effects of commonly used cytotoxic chemotherapies such as 
temozolomide (TMZ), illustrating the potential for exploiting combinations 
between PARPi and these commonly used drugs.  
 
Temozolomide 
 
TMZ is a cytotoxic chemotherapy used in the treatment of anaplastic 
astrocytomas and glioblastoma multiforme (GBM). TMZ mediates its cytotoxic 
effect by attaching alkyl (CnH2n+1) groups to nitrogen atoms in guanine bases 
in DNA (Newlands et al. 1997). As early as 1996, preclinical data established 
that 3-aminobenzamide (3-AB), a toolbox PARPi, enhanced the cytotoxic 
effect of this alkylating agent (Boulton et al. 1999; Wedge et al. 1996), 
observations which have subsequently been replicated using more specific 
and potent clinical PARPi (Gill et al. 2015). The synergistic interaction 
between PARPi and TMZ appears to be, at least in part, dependent upon the 
ability of PARPi to trap PARP on DNA (Gill et al. 2015; Murai et al. 2014a; 
Wedge et al. 1996). For example olaparib, which has a greater ability to trap 
PARP1 on DNA than veliparib, also enhances the cytotoxic effect of TMZ to a 
greater extent than veliparib (Murai et al. 2014a). The PARPi/TMZ synergistic 
effect is also seemingly not reliant upon defective HR (Gill et al. 2015) rather it 
appears to be related to the role of PARP1 in the repair of abasic sites in 
DNA, i.e. short “gaps” in the double helix that lack a base. Abasic sites, an 
intermediary state formed during repair of alkylated DNA, are processed by 
the APE1 enzyme (apurinic/apyrimidinic endonuclease 1), which generates 1-
nucleotide gaps flanked by 3′-OH and 5′-deoxyribose phosphate (5′-dRP) 
groups (Hazra et al. 2007). PARP1 preferentially binds DNA lesions with 5′-
dRP ends, as opposed to 5′-phosphate ends, perhaps explaining why TMZ 
induces such an enhanced level of PARP DNA binding (Cistulli et al. 2004) 
and why more DNA-PARP complexes occur in the presence of TMZ, 
enhancing cytotoxic effects of efficient PARP trapping PARPi. 
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In preclinical models, PARPi/TMZ combinations have been shown to be 
effective in targeting models of DNA mismatch repair-defective leukemia, 
EWS, and GBM, including models that are normally resistant to single-agent 
TMZ (Balvers et al. 2015; Bowman et al. 1998; Daniel et al. 2009; Norris et al. 
2014; M. A. Smith et al. 2015; Tentori et al. 1999). In some cases a 
PARPi/TMZ combination has been seen to enhance the apoptotic rate of a 
population of cells by decreasing expression levels of MCL-1, a key anti-
apoptotic mediator, and by increasing levels of pro-apoptotic factors such as 
BAX and BAK (Engert et al. 2015). In addition, high-dose PARPi treatment in 
concert with low-dose of TMZ is able to potentiate TMZ efficacy; dose-limiting 
toxicity is often a feature of TMZ treatment and therefore a combinatorial 
approach that uses a low dose of TMZ with an elevated dose of a PARP 
inhibitor might reduce toxicity while maintaining efficacy (M. A. Smith et al. 
2015). 
 
Based on the early pre-clinical work identifying the PARPi/TMZ inhibitor 
synergy, the first human trial using a clinical PARPi assessed whether a 
therapeutic window could be achieved with a PARPi/TMZ combination 
(Plummer et al. 2008). In this Phase 1 trial, a dose-escalation study was 
performed in patients with advanced malignancy and a combination dose 
regime of 12 mg/m2 of rucaparib plus 200 mg/m2 TMZ was established as 
tolerable (Plummer et al. 2008). Building on these results, a number of 
subsequent clinical trials have been performed to attempt to identify anti-
tumour efficacy using PARPi/TMZ combinations but also to identify and/or 
validate biomarkers that might predict which patients might receive the most 
benefit from this approach. However, to date, results from these trials have 
been mixed. For example, a randomized Phase 1/2 study in recurrent, TMZ-
resistant glioblastoma showed that combining veliparib with TMZ, though well-
tolerated, had no additional benefit compared to TMZ, as assessed by PFS or 
overall survival (OS) (Robins et al. 2015). Similarly, Middleton et al. reported 
results from a double blind, Phase 2 study, in which patients with stage III or 
IV metastatic melanoma were treated with a combination of veliparib and TMZ 
(Middleton et al. 2015). In this trial, median PFS improved from 2 months in 
the placebo arm to 3.7 and 3.6 months for either 20 mg or 40 mg doses of the 
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PARPi, respectively (NCT00804908) (Middleton et al. 2015). However, these 
improvements in PFS failed to translate into enhanced OS (Middleton et al. 
2015). However, a possible explanation to the lack of OS benefit could be that 
veliparib is a relatively poor PARP1 trapping inhibitor, PARPi with greater 
trapping potential such as olaparib or talazoparib might be more suitable to 
combine with TMZ (Murai et al. 2014a). These trials are currently underway 
(NCT02049593). Furthermore, a biomarker to define patients where a 
PARPi/TMZ combination might achieve most benefit has yet to be identified. 
To address this, Gupta et al. recently used a panel of GBM patient-derived 
xenograft (PDX) models, and found that tumours with hypermethylation of the 
MGMT promoter responded better to a veliparib/TMZ combination than PDX 
models without this methylation biomarker (Gupta et al. 2015). Based on 
these findings, patients with MGMT promoter hypermethylated GBM are 
currently being recruited into a Phase 2/3 study evaluating the efficacy of this 
combination (NCT02152982) (Gupta et al. 2015).  
 
Platinum salts 
 
Platinum-based chemotherapy induces both intra- and interstrand crosslinks 
in DNA through covalent interaction with nucleophilic N-7 sites of purine 
residues (Siddik 2003; Sikov 2015). These crosslinks inhibit DNA synthesis by 
preventing RNA polymerase II from past the site of the DNA adduct 
progressing. This may result in collapse of replication forks, and 
subsequently, the formation of DNA double stand breaks (DSBs) or single 
strand breaks (SSBs) (W. H. Ang et al. 2010). An intact nucleotide excision 
repair (NER) pathway is required for the correction of platinum-induced 
crosslinks; cells lacking functional NER show exquisite sensitivity to platinum 
agents (Husain et al. 1985; Zamble et al. 1996).  
 
Extensive preclinical data combining platinum-based chemotherapies, such 
as cisplatin, carboplatin, or oxaliplatin, with PARPi has demonstrated that 
PARPi can enhance anti-tumour efficacy independent of PARP catalytic 
inhibition (Murai et al. 2014a; Nguewa et al. 2006). Early in vivo studies 
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showed that a cisplatin-resistant rat ovarian cancer cell line model responded 
to nicotinamide-induced PARP inhibition (G. Chen and Zeller 1993). 
Subsequently, a considerable amount of data has shown PARP inhibition can 
potentiate the chemotherapeutic effect of platinum agents and increase DNA 
damage in tumour cells including in a BRCA1/2 deficient setting (Donawho et 
al. 2007; Miknyoczki et al. 2003; Rottenberg et al. 2008; Xu et al. 2015).  
Importantly, Donawho et al. showed that a PARPi/platinum combination 
resulted into a sustained and statistically significant regression of tumour 
growth in breast cancer xenografts (Donawho et al. 2007). 
 
Despite this promising data, a recent study by Murai et al. has suggested that 
the extent of synergy achieved with PARPi/platinum combinations is minimal 
compared to other combinations, particularly the combination of PARPi with 
TMZ (Murai et al. 2014a). Miknyoczik et al. found that PARPi did not alter the 
quantity of cisplatin-induced DNA adducts, but rather the repair of such 
adducts was delayed (Miknyoczki et al. 2003; Plooy et al. 1984), supporting 
the observation that PARPi do not potentiate platinum sensitivity, but rather 
the combinatorial effects observed are additive (Murai et al. 2014a). 
Additionally, a retrospective analysis on a cohort of PARPi treated, BRCA 
mutant ovarian cancer patients showed that some patients who become 
resistant to PARPi therapy maintain the potential to benefit from subsequent 
chemotherapeutic treatment, including platinum agents (J. E. Ang et al. 2013). 
Taken together, this data suggests a PARPi/platinum combination may be 
acting outside of the PARP1/BRCA synthetic lethal interaction. 
 
Several clinical trials have assessed whether a therapeutic window could be 
achieved with PARPi/platinum combinations. Balmana et al. reported 
tolerability results from a Phase 1 olaparib/cisplatin combination study in 
breast and ovarian cancer patients. A maximum tolerated dose (MTD) was 
reached with intermittent olaparib at 50 mg twice a day (b.i.d.) combined with 
cisplatin 60 mg/m2 (NCT00782574) (Balmana et al. 2014). Results from a 
Phase 1/1b study in BRCA mutated breast and ovarian cancer identified 400 
mg b.i.d. olaparib in combination with AUC5 carboplatin (once every 21-days) 
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as a tolerable dose (NCT01445418) (Lee et al. 2014). Another Phase 1 study 
evaluated the tolerability of a triple combination with PARPi given alongside 
both cisplatin and the cytotoxic chemotherapy gemcitabine (GEM) in patients 
with advanced solid tumours (NCT00678132) (Rajan et al. 2012). The 
identified MTD was 100 mg/m2 olaparib every 12 hours and 60 mg/m2 
cisplatin on day followed by 500 mg/m2 GEM on days 1 and 8. However, even 
while using suboptimal doses of both cisplatin and GEM, the addition of 
olaparib to the combination resulted in severe myelosuppresion, which may 
limit the therapeutic effectiveness of this combination moving forward (Rajan 
et al. 2012). 
 
A Phase 2, randomized trial in recurrent platinum-sensitive ovarian cancer 
reported olaparib in combination with another chemotherapy paclitaxel (PXL) 
and carboplatin followed by monotherapy olaparib improved PFS from 12.2 
months from 9.6 months in the PXL/carboplatin treated arm (NCT01081951) 
(Oza et al. 2015). The most common AE observed in this trial was 
neutropenia, reported in 43% of patients (Oza et al. 2015).  Van der Noll et al. 
reported patients initially treated with combination olaparib plus carboplatin or 
PXL followed by maintenance mono-olaparib therapy exhibited a prolonged 
favorable response (NCT00516724) (van der Noll et al. 2015). Efforts to 
identify a patient subset and/or predictive biomarker would significantly 
advance this area; such studies are currently underway. 
 
Taxanes 
 
Taxanes, for example paclitaxel (PXL) and docetaxol (DOC), are a class of 
anticancer drugs that induce mitotic arrest by polymerizing tubulin and 
inhibiting the disassembly of microtubules (Horwitz et al. 1986). Since its 
development in the 1960s, PXL has been approved for use in the treatment of 
breast, ovarian, non-small cell lung carcinoma (NSCLC), and sarcomas 
(Barbuti and Chen 2015). PXL is also currently under evaluation for activity in 
several other cancer types (Barbuti and Chen 2015). For example, in 
advance-stage gastric cancer, response rates from PXL monotherapy range 
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from 15 to 21% and PXL therapy extends OS by an average of eight months 
(Sakamoto et al. 2009). As a result, PXL has become widely used as a 
second-line therapy in gastric cancers (Hironaka et al. 2013).  
 
In preclinical studies, synthetic lethality between deficiency of the DNA repair 
sensor, ATM (ataxia telangiectasia mutated), and PARPi was identified and 
subsequently confirmed in ATM defective gastric tumour cell lines (Kubota et 
al. 2014; McCabe et al. 2006). As discussed above, PLX is widely used in 
gastric cancer and because roughly 60% of gastric cancers exhibit some form 
of ATM defect, a PARPi/PXL combination was proposed as a therapeutic 
approach in this patient population (Haince et al. 2007; Kang et al. 2008). In a 
randomized, double blind Phase 2 trial in recurrent or metastatic gastric 
cancer an olaparib/PXL combination elicited an average OS of 13.1 months 
compared to 8.3 months in a cohort of patients who received only PXL 
(NCT01063517) (Bang et al. 2015). Additionally, when patients were 
dichotomized by tumour expression of ATM (assessed by tumour biopsy 
immunohistochemistry), those with reduced ATM expression exhibited an OS 
benefit compared to those with higher ATM expression. As a result of this 
promising data, an olaparib/PXL combination is now been evaluated in a 
Phase 3 study (NCT01924533). 
 
Extensive preclinical data have characterized two main mechanisms of taxol 
resistance: (i) modulation of tubulin which impairs the effectiveness of taxol 
binding and (ii) upregulation of drug efflux pumps (Cabral et al. 1983; Horwitz 
et al. 1986; Monzo et al. 1999; Roy and Horwitz 1985). Upregulation of PGP 
drug efflux pumps has been observed as an in vitro resistance mechanism to 
PARPi (Henneman et al. 2015). As a potentially shared mechanism of 
resistance in a PARPi/taxane combination, future studies should include serial 
evaluation of modulation of drug efflux pump levels and other potential 
mechanisms of resistance.  
 
Gemcitabine  
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Gemcitabine (GEM), a deoxycytidine analog, prevents DNA synthesis when 
incorporated into DNA by preventing chain elongation during DNA replication 
(Gandhi et al. 1996; P. Huang et al. 1991). Cells exposed to GEM exhibit 
increases in DNA replication stress, stalled replication forks, and dependency 
on cell cycle checkpoints (Karnitz et al. 2005). GEM has been used both as 
single agent, and more recently in combination with radiation for the treatment 
of advanced pancreatic cancer (Loehrer et al. 2011).  
 
Resistance to single agent GEM limits the overall response rate in pancreatic 
cancer to 20%, and therefore, drug combination strategies that might extend 
the therapeutic potential of GEM (El-Rayes and Philip 2003; Schniewind et al. 
2004). Preclinical studies showed a combination of PARPi/GEM caused a 
more sustained retardation of cell proliferation, enhanced the retention of DNA 
damage and ultimately increased apoptosis in pancreatic and triple-negative 
breast cancer cell lines (Hastak et al. 2010; Jacob et al. 2007). 
 
Evaluation of tolerability and therapeutic potential of a PARPi/GEM 
combination was evaluated in a Phase 1 dose escalation / dose expansion 
clinical trial. Patients with advanced pancreatic solid tumours were treated 
with either GEM alone or a combination of olaparib/GEM (NCT00515866) 
(Bendell et al. 2015). During the dose escalation phase, tolerability of 
continuous olaparib (100 mg b.i.d.) alongside 800 mg/m2 GEM had 2/3 
patients experiencing DLT with grade 3 or higher AEs. Consequently, 
intermittent dosing of olaparib (days 1-14) 100 mg b.i.d. was evaluated with a 
reduced dose of 600 mg/m2 GEM. This combination, deemed the MTD, 
showed good tolerability. However, in the dose expansion phase of this trial, 
26/47 (55%) of patients experienced considerable haematological toxicity, 
suggesting a PARPi/GEM may be limited clinically.  
 
 
Topoisomerase inhibitors/poisons 
 
Topoisomerases are responsible for catalysing the formation of DNA strand 
breaks, which are required to alleviate the torsional structure of DNA prior to 
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naturally occurring processes such as DNA replication (Champoux 2001). 
Topoisomerase enzymes are classified as type 1 topoisomerases (Top1), 
which cut the DNA phosphodiester backbone one strand at a time, generating 
single strand DNA breaks (SSBs) and type 2 topoisomerases (Top2), which 
excise both strands of the DNA backbone simultaneously, generating double 
strand DNA breaks (DSBs).  
 
Topoisomerase 1 poisons 
 
Derivatives of the Top1 poison camptothecin (CPT), topotecan, irinotecan and 
belotecan, are used clinically; each of which covalently fix (poison) Top1 onto 
DNA and generate unrepaired SSBs (Hsiang et al. 1985). Dose limiting 
toxicities still hinder the wide-scale application of Top1 poisons but these still 
remain therapeutically viable options for several malignancies, including 
ovarian, gastric, colorectal and esophageal cancers as well as glioblastomas 
and sarcomas (Pommier 2013).  
 
PARP1 is critical for the repair of Top1 cleavage sites in DNA (L. M. Smith et 
al. 2005) and utilization of PARP inhibitors block the repair of topoisomerase 
poison-induced SSBs (Kummar et al. 2011).  Specifically, PARP1 is required 
for the recruitment of TDP1 (tyrosyl-DNA phosphodiesterase 1), a key 
enzyme for Top1-induced DNA lesion repair, to the damage site (Das et al. 
2014). This mechanistically supports observations of synergy between SN-38, 
the active metabolite of irinotecan, and olaparib (Tahara et al. 2014). 
Moreover, in contrast to TMZ, where PARP1 trapping appears to be critical for 
the synergy with PARPi, the synergy between Top1 poisons and PARP 
inhibitors is more reliant upon catalytic inhibition of PARP1 and less 
influenced by the trapping ability of PARPi. For example, the poor PARP-1 
trapper but effective PARP1 catalytic inhibitor veliparib effectively synergizes 
with irinotecan and camptothecin but not TMZ (Murai et al. 2014a). Therefore, 
discrimination between PARPi on their ability to catalytically block PARP1 
function is necessary for future evaluation of potential efficacy of a 
PARPi/Top1 inhibitor combination.  
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In initial Phase 1 clinical trials evaluating the tolerability of a PARPi/Top1 
combination, the combination of PARPi and topotecan was stopped following 
the negative results showed patients experienced increased AE with 
subtheraputic doses of the cytotoxic chemotherapy (Sanz et al. 2009).  
Specifically, when combined with 10 mg veliparib, topotecan was only 
tolerated at a dose of 0.6 mg/m2 due to hematological toxicities, significantly 
compromising the effectiveness of topotecan (Kummar et al. 2011).  However, 
this trial showed clinical mechanistic interaction between a PARPi (veliparib) 
and a Top1 inhibitor retards repair of Top1-mediated DNA damage, 
suggesting additional clinical evaluation may be warranted if better tolerability 
can be achieved (Kummar et al. 2011).  
 
Topoisomerase 2 inhibitors / poisons 
 
Topoisomerase 2 (Top2) enzymes generate staggered double strand breaks 
to aid the removal of supercoils in the DNA structure, a prerequisite for 
processes such as transcription and replication, and utilize ATP to reseal the 
nick (Champoux 2001; Lodish H 2000). Small molecules that target Top2 can 
be classified as those that impair catalytic (ATP) turnover (Top2 inhibitors 
such as bisdioxopiperazines, novobiocin, and the anthracycline, aclarubicin) 
and Top2 poisons  (which include the majority of clinically active agents 
including etoposide and doxorubicin) that fix Top2 on DNA increasing the 
frequency of Top2-DNA complexes (Nitiss 2009). Catalytic Top2 inhibitors are 
believed to cause cell death by eliminating essential Top2 enzymatic activity 
(Nitiss 2009).  While Top2 poison-generated Top2-DNA complexes result in 
DSBs independent of DNA replication(Nitiss 2009). 
 
Evaluation of a PARPi/etoposide combination in a Phase 1 dose escalation 
study demonstrated a triple combination of 100 mg dose of veliparib with 
cisplatin (75 mg/m2 on day 1) plus etoposide (100 mg/m2 on days 1-3) in a 21-
day cycle is well tolerated in treatment-naive small cell lung cancer (SCLC) 
(NCT01642251) (Owonikoko et al. 2015). Out of the nine patients enrolled in 
the study, minimal AE were observed (Owonikoko et al. 2015). 
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Doxorubicin (DOX; also known as Adriamycin) is an anthracycline 
chemotherapy that intercalates into DNA (Gewirtz 1999; Hortobagyi 1997). In 
doing so, DOX impairs the activity of the Top2 enzyme (Gewirtz 1999). 
Pegylated liposomal DOX (PLD) is an approved treatment in patients with 
epithelial ovarian carcinoma (EOC) that presented with either de novo 
resistance or recurrent disease following first-line, platinum-based 
chemotherapy (Gordon et al. 2001). A retrospective analysis of over 14 
randomized controlled trials showed overall PLD was better tolerated than 
paclitaxel in combination with carboplatin (the previous standard therapy) and 
showed some efficacy in platinum-sensitive relapsed EOC (Lawrie et al. 
2013). Because the best responses to single agent PARPi was observed in 
platinum-sensitive disease, evaluating the potential of PLD combined with a 
PARPi was a logical next step (Fong et al. 2009).  
 
To compare the efficacy of monotherapy of olaparib or PLD, 97 patients with 
advanced ovarian carcinoma who progressed within 12 months of platinum-
based chemotherapeutic treatment were randomized into three study arms: (i) 
200 mg b.i.d. of olaparib, (ii) 400 mg b.i.d. of olaparib, or (iii) intravenous 
infusions of PLD 50 mg/m2 in a 28-day cycle (NCT00628251) (Kaye et al. 
2012). As a monotherapy, olaparib failed to reach the primary objective of 
improving PFS, partly due to a better PFS observed in the PLD arm than 
expected. PFS were seen in 8/32 in the 200 mg, 10/31 in the 400 mg, and 
6/33 patients in the PLD arms. No notable difference in OS was observed 
while twice as many grade ≥ 3 toxicities were seen in the PLD arm. Though 
reported as a negative study, this trial showed consistent response and 
decreased toxicity with the use of single agent olaparib in BRCA mutation 
ovarian cancer patients. Moreover, 32% of patients who crossed over to the 
olaparib 400 mg twice daily arm from the PLD arm continued on PARPi 
treatment suggesting there may be continued benefit of PARPi therapy for 
patients with BRCA1/2 mutated disease after progression on PLD (Kaye et al. 
2012).   
 
To assess the efficacy of a PARPi/PLD combination, a Phase 1 dose 
escalation study was initiated in patients with advanced solid tumours 
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(NCT00819221) (Del Conte et al. 2014). This study reported 400 mg b.i.d. 
olaparib in combination with 40 mg/m2 PLD was generally well tolerated with 
either continuous or intermittent scheduling (Del Conte et al. 2014). Of the 44 
patients treated, 2 exhibited high-grade (≥ 3) dose-limiting toxicities that 
included thrombocytopenia and stomatitis. Additionally, results showed some 
antitumor activity in ovarian carcinoma patients with 33% of patients 
responding and 13/14 of the responders had ovarian cancer (Del Conte et al. 
2014). In another Phase 1 study, Landrum et al. reported the MTD of veliparib 
in combination with both PLD and carboplatin to be 80 mg orally b.i.d. in 
women with recurrent, platinum-sensitive ovarian cancer (Landrum et al. 
2015). Further evaluation of potential efficacy of a PARPi/PLD combination is 
warranted. 
 
PARPi in combination with radiation 
 
The therapeutic effect of high dose ionizing radiation (IR) arises from DNA 
damage to which some tumours are particularly sensitive (Mo et al. 2015). IR 
exposure results in the rapid activation and recruitment of PARP1 to damaged 
DNA (Satoh et al. 1993). Furthermore, PARP-1-null cell lines and mice exhibit 
exquisite sensitization to IR (de Murcia et al. 1997; Schreiber et al. 1995) and 
clinical PARPi induce radiosensitization in pre-clinical model systems 
(Chalmers et al. 2004; Jacobson et al. 1985), including in vivo tumour cell 
xenograft models. In this latter system, PARPi/IR combinations can elicit 
tumour inhibition with minimal effects on proliferating normal tissue, 
suggesting an actionable therapeutic window (Albert et al. 2007; Gani et al. 
2015).  
 
Clinical studies using PARPi/IR combinations have attempted to exploit these 
effects by enhancing the efficacy of IR without compounding normal tissue 
toxicity. For example, in a Phase 1, multicenter study, 22 patients with 
peritoneal carcinomatosis were treated with 60 cGy (on days 1 and 5 for 4 
weeks) of fractionated whole abdominal radiation alongside incremental 
escalations of veliparib (NCT01264432) (Reiss et al. 2015). This treatment 
regimen was well-tolerated and showed some disease stabilization (Reiss et 
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al. 2015). Mehta et al. have also reported results from a Phase 1, dose 
escalation study that identified the MTD for veliparib in combination with 
whole brain radiation therapy (WBRT) (NCT00649207) (Mehta et al. 2015). 
Here, 81 patients with brain metastases secondary to primary breast or 
NSCLC were treated with WBRT (30.0 or 37.5 Gy in 10 or 15 fractions) with 
oral b.i.d. dosing of veliparib (10 – 300 mg). The combination was well also 
well tolerated, and though uncontrolled, preliminary results suggest the 
combination arm exhibited increased efficacy with median survival time (MST) 
increasing from the nomogram-model-predicted MST of 4.2 months to 8.85 
months. In another Phase 1 trial, patients with rectal carcinoma were treated 
with veliparib in combination with capecitabine and radiation (NCT01589419) 
(Michael Michael 2015). Again, this combination showed good tolerability and 
complete responses were observed in 28% of patients. Further evaluation of 
PARPi/IR combination treatments is currently underway in multiple Phase 2 
clinical trials in patients with NSCLC (NCT02412371, NCT01386385). 
 
At present, it remains to be determined whether a concurrent PARPi/IR 
combination versus neoadjuvant PARPi therapy followed by IR will be more 
efficacious in a clinical setting. Additionally, efforts to identify a biomarker for 
response to a PARPi/radiotherapy combination have so far remained fruitless, 
but this would clearly facilitate the application of this combination. 
 
PARPi in combination with targeted agents  
 
Although PARP inhibitor combinations with chemotherapies and IR have 
received the most attention, a growing body of investigation has assessed the 
potential for combination therapy involving agents targeted against molecular 
targets in cancer. 
 
EGFR inhibitors 
 
EGFR, a member of the erbB family, is comprised of an extracellular ligand-
binding domain, a transmembrane portion, and intracellular tyrosine kinase 
regulatory domains (Siegelin and Borczuk 2014). EGFR-activating mutations, 
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including amplification of the EGFR gene, as well as point mutations within 
the kinase-coding domain of EGFR, have been detected in several tumour 
types, including lung, colorectal, ovarian, breast, and glioblastoma (Siegelin 
and Borczuk 2014). Targeting EGFR has been achieved clinically using either 
small molecule tyrosine kinase inhibitors (EGFR TKIs such as erlotinib and 
genfitinib) or monoclonal antibodies (mAbs such as cetuximab) which target 
epitopes in the extracellular domain of EGFR (Cohen et al. 2004; J. R. 
Johnson et al. 2005; Pirker et al. 2009).  
 
Erlotinib when combined with olaparib can elicit apoptosis in an EGFR-
overexpressing, ovarian cancer cell line model with wild-type BRCA function 
(Sui et al. 2015). Furthermore some EGFR mutations have been proposed to 
elicit Fanconi anemia-like phenotypes, reducing cells to a HR deficient state 
similar to that generated by BRCA gene mutation i.e. BRCAness (Pfaffle et al. 
2013), potentially explaining the rationale for a PARPi/EGFRi combinatorial 
effect.  
 
IGF-1R inhibitors 
 
Insulin-like growth factor type 1 receptor (IGF-1R), is activated by the ligands 
insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2), 
and has been implicated in the pathogenesis of several cancer types, 
including breast and colorectal cancers (H. X. Chen and Sharon 2013). 
Similar to EGFRi, IGF-1R inhibitors  (IGF-1Ri) are either monoclonal 
antibodies against IGF-1R / IGF-1R ligands (IGF-1 and IGF-2) or TKIs, such 
as OSI-906 and BMS-754807 (H. X. Chen and Sharon 2013). 
 
In preclinical models, BRCA1-mutated ovarian and breast tumour cells with 
impaired HR function have been linked to hyper activation of IGF-1R, resulting 
in an increased sensitivity to IGF-1R inhibition, suggesting BRCA-deficient 
cells may be hyper-vulnerable to dual inhibition of PARP and IGF-1R (Amin et 
al. 2015). Additionally, in HR proficient cells, IGF-1Ri exposure was found to 
reduce RAD51 mRNA transcript and protein levels and enhance sensitivity of 
these cells to olaparib (Amin et al. 2015). Taken together, this data suggests 
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cells may be reliant on IGF-1R for functional HR, and therefore, IGF-1R 
inhibition may potentiate PARPi sensitivity by generating BRCAness. 
 
VEGFR inhibitors 
 
Combinations of vascular endothelial growth factor receptor inhibitors 
(VEGFRi) with several chemotherapies have already been licensed for 
treatment in metastatic colorectal cancer, renal cancer, and advanced non-
squamous non-small cell lung cancer (Escudier et al. 2010; Hurwitz 2004).  
These approvals include the use of bevacizumab, a VEGFRi which 
sequesters VEGF-dependent signalling by competitively inhibiting the binding 
of its ligand, and cediranib, an oral ATP-competitive VEGFR1/2/3 tyrosine 
kinase inhibitor (Tewari 2015). Central to the proposed mechanism of action 
of these VEGFRi is their role in inhibiting tumour angiogenesis and current 
clinical studies are also evaluating bevacizumab plus cediranib combinations, 
as these inhibitors have non-overlapping mechanisms of actions targeting the 
extracellular and intracellular domains of VEGFR, respectively (Hong et al. 
2014). Extensive preclinical data suggests angiogenesis and VEGFR 
orchestrates a particularly pivotal role in the development of ovarian cancers, 
specifically vascular endothelial growth factor A (VEGF-A) overexpression 
and its role in vascular permeability and the development of ascites in 
epithelial ovarian cancers (EOCs) (Byrne et al. 2003). Accordingly, significant 
efforts have been made to evaluate efficacy of VEGFRi within EOC. 
Specifically, patients with recurrent, platinum-resistant EOC exhibited a 
response rate of 18% and 19% for bevacizumab and cediranib, respectively 
(Cannistra et al. 2007; Matulonis et al. 2009). 
 
Extensive preclinical data suggests induction of a hypoxic state, as is 
sometimes caused by restricting angiogenesis, can generate BRCAness, 
specifically by decreasing BRCA1 and RAD51 expression (Bindra et al. 2005). 
For example, anti-angiogenesis therapies, including bevacizumab and 
cediranib induce a higher incidence of hypoxia, a reduction in HR, and 
subsequent sensitivity to PARP inhibition (Chan and Bristow 2010; Hegan et 
al. 2010).  Additionally, inhibition of VEGFR-3 results in down-regulation of 
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BRCA1 and BRCA2 expression and can restore chemosensitivity in ovarian 
cancer models (Lim et al. 2014). 
 
Several trials have assessed whether these observations are clinically 
actionable using PARPi/VEGFRi combinations. The safety and toxicity of an 
olaparib/bevacizumab combination was assessed in a Phase 1 study and 
showed no dose-limiting toxicities (Dean et al. 2012). Results from a 
randomized, Phase 2 study in recurrent platinum-sensitive, ovarian cancer 
showed that olaparib in combination with cediranib improved PFS from 9.0 
months (monotherapy of olaparib) to 17.7 months (olaparib plus cediranib 
NCT01116648) (Liu et al. 2014). Eight patients (6 with BRCA gene mutant 
disease) had complete responses in the olaparib/cediranib combination arm 
compared to two in the olaparib monotherapy arm (Liu et al. 2014). Consistent 
with the preclinical data, this study supports the hypothesis that the 
combination of PARPi with anti-angiogenic agents may function synergistically 
and may serve as a viable treatment option for patients with platinum-
sensitive, ovarian disease. 
 
HDAC inhibitors  
 
Histone deacetylases are critical for functional HR and modulate DSB repair 
pathways (Ha et al. 2014; Kachhap et al. 2010).  Preclinical data has shown in 
PTEN-functional, triple negative breast cancer (TNBC) the combination of 
olaparib and suberoylanilie hydroxamic acid (SAHA), an HDAC inhibitor, 
synergistically increased tumour cell death via activation of apoptosis and 
increased accumulation of DNA damage (Min et al. 2015). Additionally, HDAC 
inhibitors combined with olaparib in pancreatic cancer cell lines exhibited 
downregulation of HR-related protein expression, specifically RAD51 and 
BRCA1, and accumulation of DNA damage, as measured by H2AX foci 
(Chao and Goodman 2014).  This data suggests treating cells with HDAC 
inhibitors may prime cells for PARPi sensitivity, allowing an accumulation of 
DNA damage to increase the amount of unrepaired DNA lesions past an 
apoptotic initiation threshold. It has yet to be determined whether this 
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combination will have a therapeutic window in a clinical setting or what a 
predictive biomarker of combinatorial sensitivity might be. 
 
PI3K/mTOR inhibitors 
 
Phosphoinositide 3-kinase (PI3K) signalling is fundamental to a variety of 
cellular processes, including double strand break repair (DSBR) (Kao et al. 
2007; Kumar et al. 2010). PIK3CA (which encodes the PI3K catalytic isoform 
p110α) and PTEN (phosphatase and tensin homolog) are two of the most 
frequently mutated oncogene and tumour suppressor genes, respectively, in 
human cancer. Over a dozen PI3K inhibitors (PI3Ki) are currently in clinical 
development, and in 2014, Gilead's first-in-class PI3Ki, idelalisib, received 
FDA approval for the treatment of chronic lymphocytic leukaemia (CLL) and 
non-Hodgkin's lymphoma (Fruman and Rommel 2014). However, despite this 
approval, trial results have been disappointing; substantial and sustained 
responses to single agent PI3Ki therapy remain limited for this class of 
inhibitors (Fruman and Rommel 2014).  
 
Recent data has implicated PI3K-signaling with the detection of DNA breaks, 
as well as the maintenance of BRCA1 and BRCA2 expression (Fruman and 
Rommel 2014). Therefore, abrogation of PI3K signalling has been proposed 
as an approach to debilitate HR and therefore potentiate PARPi therapy, 
potentially independent of BRCA gene mutation status. Juvekar et al. 
demonstrated that PARPi and PI3K inhibitors (PI3Ki) synergize in both BRCA-
deficient and BRCA-proficient preclinical models (Juvekar et al. 2012). 
Specifically, the PARPi/PI3Ki combination enhanced tumour cell death by 
reducing the localization of another key DNA repair protein, 53BP1, and by 
decreasing proliferation in BRCA-deficient models (Juvekar et al. 2012; Yi et 
al. 2015). Additionally, in BRCA-proficient TNBC cells, blocking PI3K 
signalling results in retardation of HR, sensitization to PARPi, and increased 
radiation-induced cell death (Ibrahim et al. 2012; Jang et al. 2015). The 
inhibition of the related mTOR signalling cascade, has also been assessed in 
combination with PARPi. Mo et al. demonstrated that in BRCA-proficient 
TNBC tumour cell models, a combination of everlimous with talazoparib 
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synergistically interacted to increase overall efficacy of either agent alone (Mo 
et al. 2015). Mo et al. also found that mTOR modulates SUV39H1, a H3K9 
histone methyltransferase involved in DSB repair. Subsequently, mTOR 
inhibition results in a decrease of SUV39H1 and a decrease in DSBR 
(Ayrapetov et al. 2014).  
 
On the basis of these pre-clinical studies, Phase 1 clinical trials assessing the 
tolerability of PARPi/PI3Ki combinations using olaparib with buparlisib 
(BKM120), BYL719, AZD5363, or AZD2014 are currently underway 
(NCT01623349, NCT02338622, NCT02576444). At present, preliminary 
findings suggest in women with HGSOV or TNBC, olaparib/buparlisib 
(BKM120) combination is well tolerated, with some evidence of anti-tumour 
effects in patients with germline mutations in BRCA genes (NCT01623349) 
(Matulonis et al. 2015). 
 
HSP90 inhibitors 
 
HSP90 is an ATP-dependent chaperone protein responsible for the 
modulation, stabilization, and activation of more than 200 proteins (Neckers 
2007; Whitesell and Lindquist 2005). Preclinical data for PARPi/HSP90 
inhibitor (HSP90i) combinations demonstrated that 17-AAG, an HSP90i, 
combined with olaparib can increase olaparib sensitivity of HR-proficient 
epithelial ovarian cancer cell lines (Choi et al. 2014). Specifically, 17-AAG 
decreases HR in the presence of DNA damage, placing the cells in a HR-
deficient-like state (Choi et al. 2014). In addition, Johnson et al. found that 
BRCA1 function is dependent upon HSP90, with the proper folding of BRCA1 
and its subsequent activity being HSP90 reliant (N. Johnson et al. 2013). 
Moreover, when treated with the HSP90i 7-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG), PARPi-resistant cells exhibited a 
decrease in the quantity of mutant BRCA1 protein, suggesting HSP90 is 
involved in folding and stabilizing mutant BRCA1, as well as functional 
BRCA1 protein. No changes in BRCA1 protein levels were observed in 
BRCA-WT cells suggesting HSP90 is only instrumental in the folding of 
mutant BRCA1 protein. Taken together, this data suggests a PARPi/HSP90i 
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combination could be an effective treatment strategy to potentiate PARPi 
therapy in an HR-proficient setting, including in BRCA mutant cancers that 
gain secondary reversion mutations that might somewhat alter the normal 
folding of the protein. This combination is currently being evaluated for 
tolerability in a Phase 1 trial (NCT02627430).  
 
CHK1/2 inhibitors 
 
Cells harboring mutations in the tumor suppressor protein TP53, which lack 
the G1 checkpoint, leave them heavily reliant on checkpoint kinases, such as 
CHK1 and CHK2, that tightly regulate G2/M progression. The majority of 
BRCA-mutant cancers harbor co-occurring mutations in TP53. It has been 
suggested that combining CHK inhibitors (CHKi) with chemotherapeutic 
agents result in a lethal accumulation of DNA damage alongside unregulated 
cell cycle progression (Morgan et al. 2010). Booth et al. showed combining 
any one of four different PARPi (olaparib, veliparib, rucaparib, and NU-1025) 
with the CHKi, AZD7762, LY2603618, or UCN-01, increased the overall DNA 
damage burden and caused cell death in BRCA-proficient breast carcinoma 
cell lines (Booth et al. 2013). Booth and colleagues also found that tumour 
betacells (which secrete insulin) pre-treated with a PARPi/CHKi combination 
were hypersensitive to radiotherapy resulting in increased H2AX levels 
(Booth et al. 2013). Currently, this combination has not as yet been assessed 
in clinical trials.  
 
Trastuzumab 
 
Overexpression or amplification of the ERBB2 tyrosine kinase receptor, 
HER2, is found in around 20% of breast cancers (Vu and Claret 2012). 
Trastuzumab, a monoclonal antibody targeting the extracellular domain IV of 
HER2, has been shown to promote HER2 degradation, antibody-dependent 
cytotoxicity, and suppression of MAPK/PI3K signalling in HER2-positive 
breast tumour cells (Vu and Claret 2012). Recent preclinical data evaluating 
the efficacy of PARPi in combination with trastuzumab within HER2-positive 
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disease showed breast cancer cell lines treated with a combination of either 
olaparib or rucaparib with trastuzumab notable decreases in cell proliferation 
and increases in DNA damage accumulation (Garcia-Parra et al. 2014). 
Further preclinical evaluation is needed to elucidate the potential of a 
PARPi/trastuzumab combination. 
 
Anti-endocrine agents 
 
Endocrine therapy that impairs signalling cascades mediated by estrogenic or 
androgenic hormones are central to the treatment of hormone-receptor 
positive cancers. In estrogen receptor positive breast cancer, inhibitors of 
estrogen receptor function, such as tamoxifen, and/or aromatase inhibitors 
that block estrogen synthesis are ubiquitously used. In prostate cancer, 
androgen receptor modulators, such as enzalutamide, and cytochrome 17 
(CYP17) inhibitors that block androgen synthesis, such as abiraterone, are 
approved therapies.  
 
Most patients with metastatic prostate cancer patients progress to advanced, 
castration-resistant disease (mCRPC) within two years following androgen 
deprivation therapy (Lorente and De Bono 2014). Both abiraterone and 
enzalutamide have small but significant benefit in terms of OS for patients 
with mCRPC (Fizazi et al. 2012) (Lorente and De Bono 2014).  
 
Recent genomic studies uncovered more than 19% of mCRPC exhibit at least 
one mutation in DNA-repair genes, including both BRCA1 and BRCA2 
(Robinson et al. 2015). Mateo et al. reported in TO-PARP, a multipart Phase 2 
trial, single agent olaparib showed anti-tumour activity in unselected mCRPC 
(NCT01682772) (Mateo et al. 2015). Of the 49 patients treated, 16/49 had 
confirmed mutations in at least one DNA-damage repair gene, with 14/16 
(88%) responding to olaparib (Mateo et al. 2015).  Additionally, preclinical 
data has also shown inhibition of AR results in the downregulation of DNA 
damage repair proteins and subsequent DNA damage repair (Karanika et al. 
2015).  
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Together, these observations have provided a foundation for clinical 
evaluation of PARPi/anti-androgen combinations in attempt to concurrently 
inhibit AR, generate PARPi-induced genomic instability, and trigger PARPi 
synthetic lethality. Evaluation of a PARPi/anti-androgen combination is 
currently clinical trial evaluation (NCT01576172). 
 
PARPi combined with immunotherapeutics 
 
Therapies that harness the host immune system have been revolutionary in 
the treatment of a subset of cancers (D. S. Chen and Mellman 2013). 
Currently most success has been achieved with immune checkpoint inhibitors 
such as anti-CTLA4 and anti-PD1/PDL-1. Response to these agents appears 
to correlate with the mutagenic burden of the tumour; presumably these 
mutations produce a larger number of neo-antigens, which can be recognised 
by the immune system (Rizvi et al. 2015). It is possible, therefore, that 
tumours with deficient BRCA1, BRCA2 and other HR proteins may be 
particularly sensitive to such approaches given the potentially high mutagenic 
burden in tumours with BRCAness. Moreover, the PARPi, BMN 673, has 
been shown to have immuno-modulatory effects Brca1-deficient ovarian 
tumour cell line grown in vivo in the peritoneum (J. Huang et al. 2015). In 
particular the percentage of cytotoxic CD8 T cells, B cells, and NK cells was 
increased in the peritoneal cavity of tumour-bearing mice. Taken together 
these observations have suggested the therapeutic efficacy of immune 
checkpoint blockade in combination with PARPi may have potential. 
To test this, Higuchi et al. investigated the efficacy of various immune 
checkpoint blockade agents in combination with PARPi (Higuchi et al. 2015). 
The model utilised was an in vivo tumour model of mouse Brca1-deficient 
ovarian cancer in an immune-competent host. They showed that a CTLA-4 
antibody, but not PD-1/PDL-1 blockade, synergized therapeutically with 
veliparib. This resulted in long-term survival in the majority of animals. The 
mechanism remains to be fully described but survival benefit was dependent 
on T cells and associated with elevated IFN-gamma production in the tumour 
microenvironment.  
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A number of trials investing PARPi/immunotherapy combinations are now 
being planned or are underway (for example, NCT02571725). 
 
PARP inhibitor combinations – challenges and opportunities 
 
It is clear from the data described above that there is already considerable 
evidence that combination therapies that involving PARPi could be of 
considerable utility in a wide variety of cancers. Along with others, we believe 
the re-categorization of PARPi based on their dual molecular mechanism of 
action (PARP inhibitor via catalytic inhibition or PARP poison via PARP 
trapping) is imperative to correctly identifying appropriate combinatorial 
approaches (Fojo and Bates 2013; Murai et al. 2012; Murai et al. 2014a). 
However, before the full potential of such combinations might be realised, we 
believe that there are a number of key issues require resolution. These are 
summarised below:  
 
(i) Foremost amongst the challenges facing the effective use of PARPi 
combinations is the issue of predictive biomarkers. Significant 
advances have been made in the discovery and clinical validation of 
predictive biomarkers of single agent PARPi responses, but far less 
is understood about what predicts a favourable response to PARPi 
combinations. In the absence of such biomarkers, the clinical 
development of combinatorial approaches might be problematic. In 
principle, identifying and validating such combinatorial biomarkers 
could be achieved in much the same way as the identification of 
biomarkers of single agent activity. The efforts to assess MGMT 
promoter methylation as a predictive biomarker of PARPi/TMZ 
combination responses (Gupta et al. 2015) provide one such 
example, but we believe much more activity in this area is required. 
(ii) How might the impact of resistance to single agent PARPi in BRCA 
gene mutant patients be minimised by the use of combinatorial 
therapy? At present it is not at all clear whether combinations of 
PARPi with secondary agents might delay or prevent the 
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emergence of PARPi resistance in these patients, providing a more 
durable response. Equally the sequencing and scheduling of agents 
requires attention. 
(iii) The delivery of PARPi combinations has been limited by the 
observation of dose limiting toxicities. In preclinical studies, some 
PARPi combinatorial synergies, notably PARPi/TMZ, have been 
achieved by using high-dose PARPi combined with relatively low 
doses of chemotherapy. A key question is: should more 
consideration be given to using similar “high PARPi/low chemo” 
approaches to achieve anti-tumour efficacy with well-tolerated 
regimens? This is starting to be exemplified in on-going studies, 
including NCT02049593. 
(iv) The majority of PARPi combinations identified to date involve DNA 
damaging chemotherapies, some of which might have overlapping 
mechanisms of actions (MoA) to PARPi and might therefore be 
limited by shared mechanisms of resistance. Whilst this area of 
research has been fruitful (i.e. PARPi/platinum combinations), 
perhaps more focus be given to systematically assessing PARPi 
combinations that involve drugs with clearly different MoA and 
which target distinct characteristics of tumour cells. These 
combinations might not elicit synergistic effects per se (i.e. supra-
additive drug combination effects on tumour cells) but might deliver 
more durable responses as they will likely be less limited by the 
emergence of common drug resistance mechanisms. 
(v) How might an understanding of the biology of PARPi responses be 
better used to design PARPi combination therapies? Already, there 
is an understanding of how PARPi cause tumour cell death by 
inducing an excessive level of genomic instability. Can this 
phenotype be exploited by combining PARPi with agents that 
enhance cell death programmes that are instigated by elevated 
levels of genomic instability such as the apoptotic or necroptotic 
machinery (Yuan et al. 2013)?  
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(vi) How might PARPi be combined with immunotherapeutics both in 
the context of wild-type BRCA1/2 or with BRCAness where there 
may be a higher mutagenic load?  
 
Now that the first PARPi has been licenced as a single agent, it seems 
appropriate to consider once again, how these agents might be used in 
combination. As we have described in this review, the work that has been 
carried out in the last few decades has shown that there is strong potential for 
PARPi combinatorial approaches as cancer treatments, if the considerable 
challenges can be overcome.  
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Figure 1. Proposed mechanism for PARPi combinations therapy 
Several agents are currently undergoing both preclinical and clinical 
evaluation in combination with PARPi. Combinatorial PARPi therapeutic 
rationale can be classified into three broad mechanisms: 1) increased 
accumulation of DNA damage and subsequent dependence on PARP-
mediated DNA damage repair, 2) increased levels of trapped PARP-DNA 
complexes, and 3) induction of BRCAness phenotype to elicit 
PARPi/BRCAness synthetic lethality.  
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Figure 2. Challenges and opportunities for PARPi combinations 
Though PARPi therapy holds enormous potential as a targeted therapy, 
challenges for optimising its use within a combination context remain. 
Principally, these challenges are reclassification of PARPi agents to 
distinguish between PARPi trappers and PARP catalytic inhibitors, 
identification of predictive biomarkers for each combinatorial approach, and 
avoidance of creating conditions for new DLTs. That being said, if these 
challenges are met, enormous opportunities remain for PARPi combinations 
to generate a profound and sustained anti-tumour response within the clinical 
setting.   
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